Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:30 UTC |
Salva Francisco D.Director · President and CEO
|
ConversionSeries A Convertible Non-Redeemable Preferred Stock · Derivative | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-029345 · ownership.xml · derivative · entry 2 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,064,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · price: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · derivative.exercise_date: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · derivative.expiration_date: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:30 UTC |
Salva Francisco D.Director · President and CEO
|
ConversionCommon Stock | 4,064,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-029345 · ownership.xml · nonDerivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,086,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F2 · balance_after: Includes 22,241 Incentive Stock Options held by Mr. Salva and exercisable within 60 days of June 16, 2026. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:30 UTC |
Salva Francisco D.Director · President and CEO
|
GrantStock Options (Right To Buy) · Derivative | 220,879 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001493152-26-018596 · ownership.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,879 Underlying: Common Stock · 220,879 shares Expires 2036-04-20 F1 · derivative.exercise_date: 1/3rd of the total number of shares of the Company's common stock subject to the option shall vest on the one year anniversary of the date of issuance, the Vesting Commencement Date, and 1/36th of the total number of shares of the Company's common stock subject to the option will vest each calendar month thereafter for the next two years, on the same day of the month as the Vesting Commencement Date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:30 UTC |
Staskey NormChief Financial Officer
|
GrantStock Options (Right To Buy) · Derivative | 35,524 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001493152-26-018597 · ownership.xml · derivative · entry 1 Staskey Norm · CIK 0001971477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,524 Underlying: Common Stock · 35,524 shares Expires 2036-04-20 F1 · derivative.exercise_date: 1/3rd of the total number of shares of the Company's common stock subject to the option shall vest on the one year anniversary of the date of issuance, the Vesting Commencement Date, and 1/36th of the total number of shares of the Company's common stock subject to the option will vest each calendar month thereafter for the next two years, on the same day of the month as the Vesting Commencement Date Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:29 UTC |
Whitfill TravisDirector · Chief Operating Officer
|
GrantStock Options (Right To Buy) · Derivative | 64,300 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001493152-26-018595 · ownership.xml · derivative · entry 1 Whitfill Travis · CIK 0001830178 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,300 Underlying: Common Stock · 64,300 shares Expires 2036-04-20 F1 · derivative.exercise_date: 1/3rd of the total number of shares of the Company's common stock subject to the option shall vest on the one year anniversary of the date of issuance, the Vesting Commencement Date, and 1/36th of the total number of shares of the Company's common stock subject to the option will vest each calendar month thereafter for the next two years, on the same day of the month as the Vesting Commencement Date. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:30 UTC |
Salva Francisco D.Director · President and CEO
|
PurchaseSeries C Warrants · Derivative | 4,064,050 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001493152-26-011858 · ownership.xml · derivative · entry 3 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,064,050 Underlying: Common Stock · 4,064,050 shares Expires not disclosed F3 · price: The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology. F3 · derivative.exercise_date: The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology. F3 · derivative.expiration_date: The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:30 UTC |
Salva Francisco D.Director · President and CEO
|
PurchaseSeries B Warrants · Derivative | 4,064,050 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001493152-26-011858 · ownership.xml · derivative · entry 2 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,064,050 Underlying: Common Stock · 4,064,050 shares Expires not disclosed F1 · price: The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date. F2 · derivative.exercise_date: The Series B Warrants are exercisable upon stockholder approval and will terminate 18 months following the date of stockholder approval. F2 · derivative.expiration_date: The Series B Warrants are exercisable upon stockholder approval and will terminate 18 months following the date of stockholder approval. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:30 UTC |
Salva Francisco D.Director · President and CEO
|
PurchaseSeries A Convertible Non-Redeemable Preferred Stock · Derivative | 500 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001493152-26-011858 · ownership.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 4,064,050 shares Expires not disclosed F1 · price: The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 22:28 UTC |
Whitfill TravisDirector · Chief Operating Officer
|
GrantStock Options (Right To Buy) · Derivative | 23,724 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-25-028849 · ownership.xml · derivative · entry 1 Whitfill Travis · CIK 0001830178 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,724 Underlying: Common Stock · 23,724 shares Expires 2035-12-19 F1 · derivative.exercise_date: 25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 22:28 UTC |
Salva Francisco D.Director · President and CEO
|
GrantStock Options (Right To Buy) · Derivative | 59,309 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-25-028846 · ownership.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,309 Underlying: Common Stock · 59,309 shares Expires 2035-12-19 F1 · derivative.exercise_date: 25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 22:28 UTC |
Ryan BarbaraDirector
|
GrantStock Options (Right To Buy) · Derivative | 3,003 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-25-028845 · ownership.xml · derivative · entry 1 Ryan Barbara · CIK 0001827169 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,003 Underlying: Common Stock · 3,003 shares Expires 2035-12-19 F1 · derivative.exercise_date: 25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 22:28 UTC |
Staskey NormChief Financial Officer
|
GrantStock Options (Right To Buy) · Derivative | 15,015 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-25-028848 · ownership.xml · derivative · entry 1 Staskey Norm · CIK 0001971477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,015 Underlying: Common Stock · 15,015 shares Expires 2035-12-19 F1 · derivative.exercise_date: 25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 22:28 UTC |
Schroer John R.Director
|
GrantStock Options (Right To Buy) · Derivative | 3,003 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-25-028847 · ownership.xml · derivative · entry 1 Schroer John R. · CIK 0001744578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,003 Underlying: Common Stock · 3,003 shares Expires 2035-12-19 F1 · derivative.exercise_date: 25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 01:51 UTC |
Staskey NormChief Financial Officer
|
PurchaseCommon Stock | 47,600 | $0.21 | $10,034.08 |
DisclosureSEC source: 0001493152-24-012606 · ownership.xml · nonDerivative · entry 1 Staskey Norm · CIK 0001971477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,100 F1 · price: The reported shares were purchased in the open market in multiple transactions at prices ranging from $0.20 to $0.2168 . The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Azitra, Inc., any stockholder of Azitra, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 01:42 UTC |
Whitfill TravisDirector · Chief Operating Officer
|
PurchaseCommon Stock | 15,000 | $0.30 | $4,500.00 |
DisclosureSEC source: 0001493152-24-006916 · ownership.xml · nonDerivative · entry 1 Whitfill Travis · CIK 0001830178 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,500 Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 01:39 UTC |
Staskey NormChief Financial Officer
|
PurchaseCommon Stock | 3,300 | $0.30 | $990.00 |
DisclosureSEC source: 0001493152-24-006914 · ownership.xml · nonDerivative · entry 1 Staskey Norm · CIK 0001971477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 01:38 UTC |
Salva Francisco D.Director · President and CEO
|
PurchaseCommon Stock | 333,300 | $0.30 | $99,990.00 |
DisclosureSEC source: 0001493152-24-006912 · ownership.xml · nonDerivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,300 Read SEC document |
| September 08, 2023 Filed Oct 3, 2023 20:05 UTC |
Staskey NormChief Financial Officer
|
GrantStock Options (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001493152-23-035230 · ownership.xml · derivative · entry 1 Staskey Norm · CIK 0001971477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 25% of the shares of the Company's Common Stock subject to the Option shall vest after 12 months of continuous service measured from 09/08/2023, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter. Read SEC document |
| September 08, 2023 Filed Oct 3, 2023 20:05 UTC |
Whitfill TravisDirector · Chief Operating Officer
|
GrantStock Options (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001493152-23-035231 · ownership.xml · derivative · entry 1 Whitfill Travis · CIK 0001830178 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,152 Underlying: Common Stock · 10,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 25% of the shares of the Company's Common Stock subject to the Option shall vest after 12 months of continuous service measured from 09/08/2023, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter. Read SEC document |
| September 08, 2023 Filed Oct 3, 2023 20:05 UTC |
Schroer John R.Director
|
GrantStock Options (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001493152-23-035229 · ownership.xml · derivative · entry 1 Schroer John R. · CIK 0001744578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 25% of the shares of the Company's Common Stock subject to the Option shall vest after 12 months of continuous service measured from 06/21/2023, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter. Read SEC document |
| September 08, 2023 Filed Oct 3, 2023 20:05 UTC |
Ryan BarbaraDirector
|
GrantStock Options (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001493152-23-035228 · ownership.xml · derivative · entry 1 Ryan Barbara · CIK 0001827169 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 25% of the shares of the Company's Common Stock subject to the Option shall vest after 12 months of continuous service measured from 06/21/2023, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries A-1 Convertible Preferred Stock · Derivative | 397,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 36 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Azitra Co-Invest I, LP Disclosed balance after: 0 Underlying: Common Stock · 397,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 22,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 35 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II NT, LP Disclosed balance after: 0 Underlying: Common Stock · 22,798 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries A-1 Convertible Preferred Stock · Derivative | 101,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 34 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II NT, LP Disclosed balance after: 0 Underlying: Common Stock · 101,842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 170,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 33 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II QP, LP Disclosed balance after: 0 Underlying: Common Stock · 170,272 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries A-1 Convertible Preferred Stock · Derivative | 412,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 32 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II QP, LP Disclosed balance after: 0 Underlying: Common Stock · 412,389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 52,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 31 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II, LP Disclosed balance after: 0 Underlying: Common Stock · 52,078 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries A-1 Convertible Preferred Stock · Derivative | 232,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 30 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II, LP Disclosed balance after: 0 Underlying: Common Stock · 232,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries A Convertible Preferred Stock · Derivative | 799,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 29 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund I, LP Disclosed balance after: 0 Underlying: Common Stock · 799,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F5 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F5 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries A Convertible Preferred Stock · Derivative | 467,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 28 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund I QP, LP Disclosed balance after: 0 Underlying: Common Stock · 467,613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F5 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F5 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 130,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 27 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 0 Underlying: Common Stock · 130,498 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 808,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 26 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 0 Underlying: Common Stock · 808,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 123,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · derivative · entry 25 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 0 Underlying: Common Stock · 123,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 436,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 21 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Azitra Co-Invest I, LP Disclosed balance after: 436,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 25,280 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 20 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II NT, LP Disclosed balance after: 137,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 111,720 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 19 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II NT, LP Disclosed balance after: 111,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 188,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 18 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II QP, LP Disclosed balance after: 1,023,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 834,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 17 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II QP, LP Disclosed balance after: 834,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 57,747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 16 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II, LP Disclosed balance after: 313,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 255,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 15 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II, LP Disclosed balance after: 255,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 799,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 14 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund I, LP Disclosed balance after: 799,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 467,613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 13 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund I QP, LP Disclosed balance after: 467,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 144,705 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 12 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 426,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
PurchaseCommon Stock | 73,708 | $5.00 | $368,540.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 11 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 282,239 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
PurchaseCommon Stock | 208,531 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 10 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 208,531 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
SaleConvertible Notes | 82,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 9 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 0 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 896,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 8 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 2,643,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
PurchaseCommon Stock | 456,412 | $5.00 | $2,282,060.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 7 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 1,747,670 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
PurchaseCommon Stock | 1,291,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 6 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 1,291,258 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
SaleConvertible Notes | 509,141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 5 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 0 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.